Epidermal disease

This early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…

This study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was …

This trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated ea…

This study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…

This study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…

This study tested a drug called imsidolimab (ANB019) in people with ichthyosis, a condition that causes dry, scaly, and red skin. The trial aimed to see if the drug could improve skin symptoms compared to a placebo. However, the study was stopped early and only enrolled 5 partici…

This study looked at whether adding platelet-rich plasma (PRP) to standard carpal tunnel release surgery helps people with severe carpal tunnel syndrome. The trial planned to enroll 15 adults with severe nerve damage. It compared surgery with PRP to surgery alone. The study was t…

This study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.

This study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.